Guohai Securities: Maintains a "buy" rating for Gushengtang (02273.HK), accelerating expansion of domestic and overseas businesses.

According to the Securities Times APP, Guohai Securities released a research report stating that it has adjusted its profit forecast for Gushengtang (02273.HK). It is expected that the company's operating income will be 3.27 billion yuan, 3.94 billion yuan, and 4.77 billion yuan in 2025, 2026, and 2027, respectively, with year-on-year growth of 8%, 21%, and 21%; net profit attributable to the mother will be 415 million yuan, 529 million yuan, and 661 million yuan, respectively, with year-on-year growth of 35%, 27%, and 25%, corresponding to PE multiples of 16 times, 12 times, and 10 times; adjusted net profit is expected to be 460 million yuan, 555 million yuan, and 671 million yuan, with year-on-year growth of 15%, 21%, and 21%. As a leading Chinese medicine medical service company, the company maintains a "buy" rating.